about
Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell ReplacementClinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes.Evaluating rate of change as an index of glycemic variability, using continuous glucose monitoring data.Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover studyHes3 is expressed in the adult pancreatic islet and regulates gene expression, cell growth, and insulin release.Comparison of Optimised MDI versus Pumps with or without Sensors in Severe Hypoglycaemia (the Hypo COMPaSS trial)Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups.Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest riskEvidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.Interventions That Restore Awareness of Hypoglycemia in Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis.Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.Technology to Reduce Hypoglycemia.Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions.Prolonged activation of human islet cannabinoid receptors in vitro induces adaptation but not dysfunction.Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit.Real-time continuous glucose monitoring significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes.Evaluation of the Effect of Carbohydrate Intake on Postprandial Glucose in Patients With Type 1 Diabetes Treated With Insulin Pumps.Hypoglycaemia: current management and controversies.Severe hypoglycaemia in type 1 diabetes mellitus: underlying drivers and potential strategies for successful prevention.Blood glucose pattern management in diabetes: creating order from disorder.Poorer glycaemic control in type 1 diabetes is associated with reduced self-management and poorer perceived health: a cross-sectional study.Multiple Daily Injections OR Insulin Pump Therapy: Choosing the Best Option for Your Patient-An Evidence-based Approach.Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range.Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of β-Cell Replacement.Who Should Be Considered for Islet Transplantation Alone?Effectiveness of Automated Insulin Management Features of the MiniMed® 640G Sensor-Augmented Insulin Pump.Taking training into your own hands.Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose ManagementSustained benefit of continuous subcutaneous insulin infusion on glycaemic control and hypoglycaemia in adults with Type 1 diabetes.First case of pancreas transplant alone in a patient with diabetes and HIV infection.Evolution and resolution of human brain perfusion responses to the stress of induced hypoglycemia.Frequency of biochemical hypoglycaemia in adults with Type 1 diabetes with and without impaired awareness of hypoglycaemia: no identifiable differences using continuous glucose monitoring.Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes.Insulin pump therapy with automated insulin suspension: toward freedom from nocturnal hypoglycemia.Dynamic Profiling of Insulin Secretion and ATP Generation in Isolated Human and Mouse Islets Reveals Differential Glucose Sensitivity.Continuous glucose monitoring in patients with insulinoma.Mesenchymal stromal cells improve human islet function through released products and extracellular matrix.Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia.Acceptability of Implantable Continuous Glucose Monitoring Sensor.Distal technologies and type 1 diabetes management.
P50
Q26769878-5B7322A1-CD27-4155-BED6-2B79AE01B494Q33727481-6EA64F52-30A8-4789-87DA-0FC413640B8FQ33896424-6A155A62-B538-4B5F-A402-5AFF6B51BF35Q34194737-E2AC8FA4-DF09-4333-BF22-1346160C0BB1Q34446322-3F122BF6-27A5-4D6E-A58D-AF135A2D07E9Q34511505-527BEF2E-1663-472A-AD38-877C73D67460Q35177261-E89F063C-5D9E-4C41-BE60-3AEC73AF7FACQ35179907-BFD87C52-1359-4CB9-AD64-6D8E329A55B3Q35630711-18351693-98E4-49AB-9BDB-D02F922F356AQ35710110-EE03FAAE-A226-4E02-99A3-84C1A05C3011Q35877744-1ED76843-A36E-47B5-A467-46D691163C94Q35918438-4080E693-D8A7-4CF0-86EE-79C1EA24C0ABQ36291620-5874194F-3D22-44DA-8FD5-67CDC693B6B2Q36799355-E4FD8C9F-2A67-4994-9423-F9B732D95A7AQ37235951-4DBF3EFB-ECC1-4A3F-9AC5-070B4102A884Q37331178-5C010CB9-F377-4B42-93A4-B8E90FE0921EQ37391381-84558F44-ED1E-436E-86C2-366359FAABF8Q37836184-073A3BF0-7537-4C18-82EF-8A7EA52138A5Q38159475-059EE584-1D3A-4088-AFE4-EDC1B3DFB456Q38172312-CD257D89-BACA-432E-8BE1-CEE2A67903B3Q38240299-450BA014-8F69-4FE0-8D11-3C1C6A3B8D33Q38580509-BF2314E7-A702-47B1-A2D1-4E1AAD215A68Q38649473-5692A895-1CB8-4C68-A40D-679C2DF7F3AFQ38809198-2544D7B1-E094-4067-8334-F6FFF4D1D997Q38907821-871A7447-4659-4C7A-BD69-29A620156860Q39347625-741EA0B6-EED4-40EB-9887-017751F41F9DQ39836719-F4DF828E-01A7-4E98-910B-9DACDE89D68CQ39975070-792569FB-DE6C-49D1-A267-834156DDFE6AQ40693872-F15E6DA8-9BD5-4EEF-931F-B1535462329BQ40705632-6F6F9764-1343-4419-B0EA-AD0F23117707Q42987276-CC07CCA6-1FA9-451F-ACBD-6FFC13A6E589Q43025065-1D5C3803-FF71-4FF1-B056-0A114F499FA9Q43145901-FFDAAFC2-68C7-4BA1-BD49-8BB206B98847Q44441580-0533CC21-AF26-4196-9415-E0030FD42AF7Q46251863-E869FA64-76B6-4AE3-AA00-DE42157E17F6Q46844251-8E4FF6F3-73C7-4E0E-963B-D3B7F897A304Q47382694-978B88E3-BBEE-4AB2-AC40-9EF6310A878CQ47567739-B29FFBB7-1263-406A-B084-A4794C87D2B6Q47589352-0A56158A-4848-4F96-B096-9AE1AAF1A1DBQ47713427-B92E96C0-3272-4F24-B1A9-20F3B4A217B3
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pratik Choudhary
@ast
Pratik Choudhary
@en
Pratik Choudhary
@es
Pratik Choudhary
@nl
type
label
Pratik Choudhary
@ast
Pratik Choudhary
@en
Pratik Choudhary
@es
Pratik Choudhary
@nl
altLabel
Choudhary P
@en
Pratik choudhary
@en
prefLabel
Pratik Choudhary
@ast
Pratik Choudhary
@en
Pratik Choudhary
@es
Pratik Choudhary
@nl
P106
P1153
25951256500
P31
P4012
P496
0000-0001-7635-4735